Despite advancements in treatment, multiple myeloma (MM) remains without a cure, nearly always developing refractoriness to 3 primary classes of standard anti-MM therapies: immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs) and anti-CD38 monoclonal antibodies (αCD38 mAbs). This evidence concerns the gene CD38 and Miyoshi myopathy.